AC Immune 
Welcome,         Profile    Billing    Logout  
 7 Products   17 Diseases  7 Products   4 Trials   576 News 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
crenezumab (RG7412) / AC Immune
API ADAD Colombia , NCT01998841: A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort

Completed
2
252
RoW
Crenezumab, MABT5102A, Placebo
Genentech, Inc., Banner Alzheimer's Institute, National Institute on Aging (NIA)
Alzheimer's Disease
03/22
08/23
ACI-7104.056 / AC Immune
VacSYn, NCT06015841: A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson's Disease

Hourglass Jun 2024 - Dec 2024 : Results from VACSYN trial for Parkinson’s disease
Recruiting
2
150
Europe
Placebo, ACI-7104.056 at Dose A, ACI-7104.056 at Dose B (optional), ACI-7104.056 at Dose C (optional)
AC Immune SA, ICON Clinical Research
Parkinson Disease, Parkinson Disease 6, Early-Onset
01/28
01/28
ACI-24 / AC Immune
2018-000445-39: A study comparing the safety and clinical effects of different formulations of a new vaccine, ACI-24 with placebo in patients with mild Alzheimer's disease

Ongoing
2
45
Europe
ACI-24, ACI-24, Suspension for injection
AC Immune SA, AC Immune SA
Alzheimer's Disease, Alzheimer's Disease, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
ABATE, NCT05462106: A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome ( Study)

Recruiting
1/2
140
Europe, US
Placebo, ACI-24.060 at Dose A, ACI-24.060 at Dose B, ACI-24.060 at Dose C, ACI-24.060 at Dose D, ACI-24.060 at Dose X, ACI-24.060 at Dose Y
AC Immune SA, Worldwide Clinical Trials
Alzheimer's Disease, Prodromal Alzheimer's Disease, Amyloid Plaque, Beta-Amyloid, Alzheimer's Disease in Down Syndrome
06/26
06/26
semorinemab (RG6100) / AC Immune
NCT03828747 / 2018-003398-87: A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

Completed
2
272
Europe, US
Semorinemab, MTAU9937A, RO7105705, Placebo, [18F]GTP1
Genentech, Inc.
Alzheimer's Disease
07/21
08/23
JNJ-2056 / J&J
Reτain, NCT06544616: A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

Recruiting
2
498
Europe, Japan, US, RoW
JNJ-64042056, Placebo
Janssen Pharmaceutica N.V., Belgium
Preclinical Alzheimer's Disease
07/31
05/33
NCT04445831: A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease

Completed
1/2
57
Europe
ACI-35.030, Placebo, JACI-35.054
AC Immune SA, Janssen Research & Development, LLC
Alzheimer's Disease, Cognitive Impairment, Tauopathies, Mild Cognitive Impairment, Dementia, Brain Diseases, Central Nervous System Diseases
09/23
09/23
JACI-35.054 / AC Immune, J&J
No trials found
ACI-24.060 / Takeda
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
crenezumab (RG7412) / AC Immune
API ADAD Colombia , NCT01998841: A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort

Completed
2
252
RoW
Crenezumab, MABT5102A, Placebo
Genentech, Inc., Banner Alzheimer's Institute, National Institute on Aging (NIA)
Alzheimer's Disease
03/22
08/23
ACI-7104.056 / AC Immune
VacSYn, NCT06015841: A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients With Early Stages of Parkinson's Disease

Hourglass Jun 2024 - Dec 2024 : Results from VACSYN trial for Parkinson’s disease
Recruiting
2
150
Europe
Placebo, ACI-7104.056 at Dose A, ACI-7104.056 at Dose B (optional), ACI-7104.056 at Dose C (optional)
AC Immune SA, ICON Clinical Research
Parkinson Disease, Parkinson Disease 6, Early-Onset
01/28
01/28
ACI-24 / AC Immune
2018-000445-39: A study comparing the safety and clinical effects of different formulations of a new vaccine, ACI-24 with placebo in patients with mild Alzheimer's disease

Ongoing
2
45
Europe
ACI-24, ACI-24, Suspension for injection
AC Immune SA, AC Immune SA
Alzheimer's Disease, Alzheimer's Disease, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
ABATE, NCT05462106: A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome ( Study)

Recruiting
1/2
140
Europe, US
Placebo, ACI-24.060 at Dose A, ACI-24.060 at Dose B, ACI-24.060 at Dose C, ACI-24.060 at Dose D, ACI-24.060 at Dose X, ACI-24.060 at Dose Y
AC Immune SA, Worldwide Clinical Trials
Alzheimer's Disease, Prodromal Alzheimer's Disease, Amyloid Plaque, Beta-Amyloid, Alzheimer's Disease in Down Syndrome
06/26
06/26
semorinemab (RG6100) / AC Immune
NCT03828747 / 2018-003398-87: A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

Completed
2
272
Europe, US
Semorinemab, MTAU9937A, RO7105705, Placebo, [18F]GTP1
Genentech, Inc.
Alzheimer's Disease
07/21
08/23
JNJ-2056 / J&J
Reτain, NCT06544616: A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

Recruiting
2
498
Europe, Japan, US, RoW
JNJ-64042056, Placebo
Janssen Pharmaceutica N.V., Belgium
Preclinical Alzheimer's Disease
07/31
05/33
NCT04445831: A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease

Completed
1/2
57
Europe
ACI-35.030, Placebo, JACI-35.054
AC Immune SA, Janssen Research & Development, LLC
Alzheimer's Disease, Cognitive Impairment, Tauopathies, Mild Cognitive Impairment, Dementia, Brain Diseases, Central Nervous System Diseases
09/23
09/23
JACI-35.054 / AC Immune, J&J
No trials found
ACI-24.060 / Takeda
No trials found

Download Options